Скачать или смотреть Orphan Drug Development, Pricing, and Access

Dennis Jackman of CSL Behring had a ‘fireside chat’ with Peter Saltonstall of the National Organization of Rare Disorders (NORD) during the latest BIO Conference.

In this clip, Jackman explains that the conversation was well received, and they discussed a number of issues, including pricing, patient involvement in the drug development process, as well as drug access.

With regard to the latter issue, Jackman said, “if the community and industry, companies like ours, are successful in developing a rare disease product, then not having access to it because of payment policies that exist or access policies by payers is really tragic. And in some cases we're seeing discriminatory or harmful elements such as high co-insurance rates for rare disease patients in specialty tiers that that hit rare disease patients much more than they would hit other patients.”

As for pricing, Jackman noted that it is important for drug companies to show the value of the drug rather than focus on pricing.